# Suzette Delaloge

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/suzette-delaloge/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,089 |
| Field | Breast Cancer Treatment Studies |
| h-index | 88 |
| i10-index | 301 |
| Last Known Institution | Institut Gustave Roussy |
| OpenAlex ID | https://openalex.org/A5083142899 |
| ORCID iD | https://orcid.org/0000-0003-2106-9165 |
| Works | 829 |

## Researcher papers

- [70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer](https://scholariq.org/papers/70-gene-signature-as-an-aid-to-treatment-decisions-in-early-stage-breast-cancer/)
- [Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy](https://scholariq.org/papers/cancer-cell-autonomous-contribution-of-type-i-interferon-signaling-to-the/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)
- [Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study](https://scholariq.org/papers/prognostic-value-of-tumor-infiltrating-lymphocytes-on-residual-disease-after/)
- [Personalized early detection and prevention of breast cancer: ENVISION consensus statement](https://scholariq.org/papers/personalized-early-detection-and-prevention-of-breast-cancer-envision-consensus/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/switch-to-fulvestrant-and-palbociclib-versus-no-switch-in-advanced-breast-cancer/)
- [Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials](https://scholariq.org/papers/prognostic-and-predictive-value-of-tumor-infiltrating-lymphocytes-in-two-phase/)
- [Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer](https://scholariq.org/papers/letrozole-and-palbociclib-versus-chemotherapy-as-neoadjuvant-therapy-of-high/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

## Researcher university

- [Institut Gustave Roussy](https://scholariq.org/institutions/institut-gustave-roussy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.